Toby A. Eyre
托比·艾尔
MBChB, DPhil, FRCP, FRCPath
Consultant Haematologist; Associate Professor血液科顾问医师；副教授
👥Biography 个人简介
Dr. Toby Eyre is a leading UK haematologist at Oxford University Hospitals, specializing in CLL, lymphoma, and their treatment with novel targeted agents including BTK inhibitors. He has pioneered research on ibrutinib-based combinations, Richter transformation biology, and novel therapeutic strategies for hard-to-treat lymphoid malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Ibrutinib Combinations in CLL and Lymphoma
Led clinical trials and translational studies of ibrutinib-based combination regimens for CLL and lymphoma in the UK, advancing understanding of BTK inhibitor synergy and mechanisms of resistance.
Representative Works 代表性著作
Ibrutinib Combined with Venetoclax in Relapsed/Refractory CLL and Richter Transformation
Journal of Clinical Oncology (2022)
Study demonstrating the efficacy and safety of dual BTK/BCL-2 inhibition in high-risk CLL and Richter transformation, informing combination targeted therapy approaches.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 托比·艾尔 的研究动态
Follow Toby A. Eyre's research updates
留下邮箱，当我们发布与 Toby A. Eyre（Oxford University Hospitals NHS Foundation Trust）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment